uploads/2018/12/Graph-9-1.png

Venclexta: A Solid Growth Driver for AbbVie in Future Years

By

Updated

Venclexta revenue trends

AbbVie (ABBV) reported global Venclexta sales worth $96 million in the third quarter, a YoY (year-over-year) rise of more than 100% on both an operational and a reported basis. As per the company’s third-quarter earnings conference call, this performance was mainly attributable to the FDA’s approval of the drug in a broader R/R (relapsed/refractory) CLL (chronic lymphocytic leukemia) indication.

The company reported Venclexta sales worth $69 million in the US market, a YoY rise of more than 100%. It also reported Venclexta sales worth $27 million in international markets in the quarter, a YoY rise of more than 100% both on a reported basis and on an operational basis.

 

As per the company’s third-quarter earnings conference call, it expects Imbruvica to report global revenue of close to $3.5 billion, of which more than $2.9 billion is expected to be earned in the US market.

Article continues below advertisement

Growth drivers

On September 11, AbbVie issued a press release announcing the FDA’s approval of the inclusion of minimal residual disease negativity data from its Phase 3 MURANO study for Venclexta’s label. As per the company’s third-quarter conference call, this marked the second label expansion for Venclexta in 2018 following the FDA’s approval of the drug in combination with rituximab in an R/R CLL indication in June.

As per the company’s third-quarter earnings conference call, MRD is quickly becoming a major objective for CLL therapies. Hence, the inclusion of these data in Venclexta’s label has further strengthened the drug’s position in CLL indications.

On October 31, AbbVie issued a press release announcing favorable results from its CLL14 Phase 3 trial comparing the combination of Venclexta and Gazyva with that of Gazyva and chlorambucil as a frontline CLL therapy.

On November 21, Venclexta was approved by the FDA in a treatment-naïve acute myeloid leukemia indication. As per the company’s third-quarter earnings conference call, confirmatory results from the Phase 3 trial for Venclexta in this indication are anticipated in 2019.

AbbVie is also studying Venclexta in R/R multiple myeloma and first-line multiple myeloma indications.

In the next article, we’ll discuss growth trends for AbbVie’s hepatitis C portfolio in 2018.

Advertisement

More From Market Realist